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Introduction
Approximately 500,000 women develop cervical can-
cer annually, resulting in an annual mortality of about
200,000 [1]. Cervical cancer is the second most com-
mon cancer among women worldwide, with an esti-
mated 1.4 million cases, 493,000 new cases, and
274,000 deaths in the year 2002 [2]. In Taiwan, cervical
cancer is not only the most frequently reported cancer
among women, but also the most common female gen-
ital tract neoplasm [3,4], with an incidence of 17 per
100,000 women in 2002 [5]. Early detection is effec-
tive, because the development, maintenance and pro-
gression of precursor lesions (cervical intraepithelial
neoplasia [CIN]) evolve slowly into invasive cancer,
typically over a period of more than 10 years. Tradi-
tionally, these precursor lesions are detected with cervical
cytology screening methods such as the Papanicolaou
(Pap) test, which has successfully lowered the inci-
dence and mortality of cervical cancer. However, up 
to 30% false-negative results [6] inherent to the Pap
test have prompted many gynecologic oncologists to
develop new tools for identifying precancerous cervical
lesions.
It is now recognized that human papillomavirus
(HPV) infection is a necessary cause for over 99% of
cervical cancers [1,7,8]. Advances in the understand-
ing of the causative role of HPV in the etiology of high-
grade cervical lesions (CIN 2/3) and cervical cancer
[7,9–11] have led to the development, evaluation and
recommendation of HPV-based technologies for cervical
cancer prevention and control. The importance of HPV
is increasingly recognized by both the medical commu-
nity and the public. HPV infection is among the most
common sexually transmitted infections (STIs) in most
populations: 15–20% in many European countries, 70%
in the USA, and 95% among high-risk populations in
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Africa [12]. HPV infection is the STI with the highest
incidence in the US; an estimated 20 million people are
currently infected, and 6.2 million persons acquire a new
infection annually [13,14]. It is estimated that 80% of
sexually active women would have been exposed to HPV
by the age of 50 [15]. The prevention of HPV infection
before the onset of CIN is now possible with the recently
available prophylactic HPV vaccines, e.g. the quadri-
valent Gardasil (Merck & Co., NJ, USA) and bivalent
Cervarix (GlaxoSmithKline, London, UK). This article
reviews recent reports and offers up-to-date available
information concerning current practices and modern
trends in the prevention of cervical cancer.
HPV Viral Genetics, Molecular Biology,
and the Life Cycle
HPV is recently recognized by the International Com-
mittee on Taxonomy of Viruses as member of the Papil-
lomaviridae family. Previous classification has grouped
papillomaviruses with polyomaviruses in the Papova-
viridae family based on various resemblances, including
similar viral capsids, lack of envelope, and their double-
stranded circular DNA genome. Both families also
share the same arrangement of 8–10 open reading
frames within the genome, and one particularly distinc-
tive characteristic is the arrangement of partly overlap-
ping open reading frames on a single strand of DNA
molecule. Nevertheless, differences in genome size and
transcriptional strategies, as well as non-homologous
proteins, have separated the polyomavirus and papil-
lomavirus into two different families [16].
Although they are widespread among higher 
vertebrates, papillomaviruses have mostly been isolated
from humans [17]. Other papillomaviruses are found
in domestic mammals, including a number of wild and
exotic mammals, reptiles, and two bird species [18–20].
Papillomaviruses exhibit strict species specificity and do
not transmit from non-primates to humans [21].
Therefore, HPVs do not induce morphologic changes
in animal tissues.
The viral genome is relatively small (~8,000 base
pairs) [22], codes for only eight proteins and can be
roughly categorized into three distinct regions: the
region of late proteins (L1 and L2); the long control
region without coding potential; and the region of early
proteins (E1–E8) [23]. The HPV early proteins E1 and
E2 produce viral proteins during viral replication and
transcription; E4 seems to assist the release of virus
from infected cells [24], and the late L1 and L2 are
structural proteins of the individual capsomere sub-
units in the viral capsid. The late protein L1 (57 kDa) 
is the major structural and antigenic capsid protein
that accounts for 80% of the viral particle, and the 
late L2 protein (43–53 kDa) is the minor, infectivity-
enhancing capsid protein. The early proteins E6 and E7
are the most important oncogenic proteins encoded by
high-risk HPV (hrHPV) types. Since the transcription of
E6 and E7 genes always occurs in cervical carcinomas,
this discovery marked the first clues to the link between
viral genes and HPV-associated tumorigenesis [25,26].
Abundant supporting evidence from tissue cultures
and animal models has demonstrated the immortaliz-
ing and oncogenic transforming potential of E6 and
E7 genes that are thought to play a role in the initia-
tion and oncogenic progression of tumors [27]. These
genes are expressed after integration into the host
genome during oncogenic progression. The early pro-
tein E6 is thought to speed turnover of the key tumor
suppressor protein p53, while E7 has been implicated
in blocking the function of retinoblastoma protein (pRB)
cell replication regulatory proteins [28]; E5 has also
been implicated in cellular transformation [29]. Since
the p53 and pRB genes are involved in the suppression
of oncogenic transformation, the binding and inac-
tivation of these cellular proteins by the E6 and E7
oncogenes are one of the mechanisms of HPV-mediated
cellular transformation.
The viral life cycle is tightly linked to the differentia-
tion program of the epithelial cell. In general, HPV infec-
tion is limited to the basal cells of a human epithelial
surface and normally remains in infected basal cells;
unlike some animal papillomavirus types, they do not
infect or express gene products in the underlying der-
mis [30]. Other cells that are also infected move away
from the basement membrane and differentiate into
mature squamous cells as they progress towards the
epithelial surface. HPV viral particles consist of the
viral DNA genome surrounded by the protein capsid,
which is composed of HPV L1 and L2 proteins. As a
result, antibodies against L1 and L2 could possibly
neutralize the virus and prevent HPV infection. Upon
infection, the early viral proteins are expressed in the
infected basal cells within the lower epithelial layers.
As infected cells reach the surface, the L1 and L2 pro-
teins are produced and allow shedding of mature virions
as virus-laden squames. Although HPV preferentially
infects squamous epithelial cells rather than columnar,
cuboidal or transitional epithelial cells [31], the infec-
tion of columnar cells can render much easier formation
of mucosal lesions, which form the basal layer of the
stratified epithelium of the transformation zone [30].
Since they have no envelope, HPVs are relatively stable
and remain infectious for months in a moist environ-
ment [21]. During infection, HPV DNA is generally
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found in the cytoplasm. However, the DNA of hrHPV
types integrates into the host genome of most cervical
tumors. Integration commonly disrupts the HPV virus
through the loss of virion production (L1 and L2 are not
expressed) and accompanies the increasing expression
of E6 and E7. Consequently, integration transforms the
infected basal cells into a malignant phenotype, ranging
from “warty” epithelium with koilocytosis to overt malig-
nancy. In other words, the steady presence of early pro-
teins E6 and E7 during hrHPV infection could produce a
therapeutic immune response.
Cervical HPV infection is usually benign. Less than
5% of women infected with HPV develop premalignant
lesions, which may progress from low-grade (CIN 1) to
high-grade lesions (CIN 2/3) as well as cervical cancer, if
they receive no medical intervention [32–34]. Infection
alone is insufficient to cause cancer, and additional fac-
tors are required for neoplasia. Approximately 70% and
91% of new infections clear up within 1 and 2 years,
respectively [35–37]. Most HPV infections are usually
transient and are not associated with any sign or symp-
tom of infection, causing no viremia or systemic mani-
festations. Most people never even know they have had
HPV, and their immune system clears up the infection
before they notice it. The nature of the immune response
that controls and eliminates HPV infections is still
under investigation; however, it almost certainly has a
role in limiting and eradicating HPV infection. It is not
known whether clearance implies that the virus is still
present at levels below detection limits of existing tech-
nologies or whether it signifies an actual eradication of
the preexisting viral infection.
HPV Infection, Genotypes, and Diseases
There are more than 100 different genotypes of papil-
lomavirus [38]. The genotyping of HPV is differentiated
primarily by the DNA sequences of the outer capsid
protein L1 and, to a lesser extent, by those on E6 and
E7. A 10% difference in DNA sequence with respect to
previously established strains is sufficient to define a new
HPV viral type. The HPV genotypes are numbered in
sequence of their discovery. Three genera of the Papil-
lomaviridae family are responsible for significant diseases
in humans: alpha-papillomavirus (includes all genital
papillomaviruses), beta-papillomavirus (papillomavi-
ruses responsible for epidermodysplasia verruciformis),
and gamma papillomaviruses (most of the viruses
responsible for cutaneous lesions) [16,39]. However, the
prior HPV classification as mucosal or cutaneous types
based on their preferred tissues is still commonly applied
clinically and will be used throughout this text. Some
HPV types cause cutaneous infections (the common
skin wart), whereas only about 40 types cause mucosal
infections, which lead to genital tract diseases in men
and women. The high-risk types of mucosal HPV, also
known as “oncogenic”, put women at high risk of devel-
oping cervical cancer, as opposed to other low-risk types
of mucosal HPV, also known as “non-oncogenic”. Based
on a review of global epidemiologic studies, Munoz 
et al [40] have classified mucosal HPV into 18 hrHPV
genotypes, 12 low-risk HPV (lrHPV), and three pre-
senting indeterminate risk. It is now recognized that
HPV-16 is the single most common hrHPV type in an-
ogenital cancer precursor lesions, CIN as well as cervical
cancers, and a subset of head and neck cancers [41–43].
The hrHPV-16 and -18 are found in 25% of all CIN 1
lesions, 70% of CIN 2/3, and anogenital cancers. HPV-
16 alone accounts for more than 50–60% of cervical
cancer cases in most countries, followed by HPV-18
(10–12%) and HPV-31 and -45 (4–5% each) [12,43,
44]; the remainder is caused by a variety of other types
that vary globally. The other 11 less common hrHPV
types (other than HPV-16, -18, -31 and -45) are HPV-
33, -35, -39, -51, -52, -56, -58, -59, -68, -73 and -82;
the three indeterminate (or probable) hrHPV types are
HPV-26, -53 and -66.
Risk Factors for HPV Infection
Sexual transmission is the dominant mechanism for
acquisition of genital HPV [35,45]. Important risk 
factors for HPV infection and development include
number of sexual partners, immunosuppression and
the risk behavior of those partners, and early onset of
sexual activity. HPV is, nonetheless, common in people
with few sexual partners [46]. The rates of HPV infec-
tion increase rapidly among women with only one life-
time partner (20% to 46%) to women with 10 or more
partners (almost 70%) [47,48]. Immunosuppression is
an important risk factor that includes those partners
infected with other STIs, receipts of an organ trans-
plant, or renal disease. Partners can be infected with
other STIs that may lead to immunosuppression, such
as HIV, chlamydia, and genital herpes [11,49,50]. Since
HIV damages the body’s immune system, HIV-infected
women are at a greater risk of HPV infection, persis-
tent HPV infection, and precancerous lesions [51–53].
An early study by Conti et al [54] reported a 42% and
8% CIN detection rate for HIV-infected and non-HIV-
infected women, respectively. HPV-infected women
who are seropositive for type 2 herpes simplex virus or
Chlamydia trachomatis infection are also at greater risk
for cervical cancer [8,12,50]. Most studies demonstrate
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that young age (usually defined as less than 25 years) is
a risk factor for infection among sexually active young
women. The transmission of HPV infection during early
years of sexual activity contributes to the higher rates in
younger women, and the infection clears over time in
most women. One study demonstrated that more than
50% of young women acquired cervical HPV infection
48 months after the first sexual intercourse [55]. The
cumulative prevalence rates are as high as 82% among
adolescent girls [56], but the rate is usually ~30% accord-
ing to many clinic-based prevalence studies in the US
[57]. Unlike most studies in the US, which revealed a
decline in HPV prevalence after the age of 25 years,
one prospective study reported an increase in preva-
lence after the age of 40 years in Guanacaste, Costa
Rica [58]. Another study estimated that 70% of sexually
active adults will become infected with HPV during their
lifetime [59]. However, the most important risk factor
for developing premalignant lesions and cervical cancer
is persistent infection with hrHPV. HPV infections are
frequent, but only a small percentage of HPV infections
become persistent. Persistent HPV carriers are estimated
to be about 3–10% of women in different populations
[60]. Persistent HPV is most commonly defined as
detection of the same-risk HPV types at two or more
visits, 4–6 months apart [61]. Studies also revealed that
persistent infection with a hrHPV is associated with a
more than 10-fold risk for the development of high-
grade cervical lesions (CIN 2/3) [62,63].
Additional risk factors for HPV infection that are less
consistent include condom use, parity, dietary factors
(nutritional deficiencies mainly related to antioxidant
agents), uncircumcised male partners, and oral con-
traceptive use [55,64–66]. Although a January 2004
Centers for Disease Control and Prevention report stated
that condom use has been associated with lower rates
of HPV-associated diseases including cervical cancer,
the efficacy of condoms in preventing HPV infections
is still unknown [67]. One study suggested that since
HPV is not transmitted through semen or bodily fluids,
condoms do not protect against infection with HPV
[68]. HPV infections are transmitted through skin-to-skin
contact often far beyond the area covered by condoms.
Another study demonstrated that non-penetrative sex-
ual activity is associated with HPV acquisition, but much
less frequently with sexual intercourse [55]. It has also
been reported that, though in very rare cases, HPV may
be transmitted non-sexually, possibly through contact
with infected urogenital secretions from sharing towels
or bathwater [69,70]. A study by Plummer et al indi-
cated an excess risk among women smokers with HPV
for promoting the progression from HPV to cervical
cancer with squamous cell histologic types for current
smokers, as well as ex-smokers; and these findings,
however, were not true for adenocarcinomas [71].
Genetic susceptibility to HPV infection appears to be
important, as reported by Magnusson et al [72,73].
These authors found that women who have a family
history of cervical cancer were almost twice as likely to
develop cervical cancer as women who did not have a
family history of the disease.
HPV Detection Methods
Unlike many pathogens, infectious virions are produced
only in the terminally differentiated cell, and this explains
why no simple in vitro culture methods are available for
identifying HPV infection. Over the years, only nude
mouse [74,75] and SCID mouse [76] xenograft sys-
tems as well as raft-culture systems [77] have achieved
limited propagation of infectious virus for some HPV
types. Serologic testing of HPV is most commonly per-
formed using an ELISA test for antibodies to type-
specific virus-like particles (VLPs). Serologic studies of
HPV are considered to be only research tools, and a
consensus guideline for standard serologic method is
not yet available. Unfortunately, current serologic test-
ing of HPV antibodies has relatively low sensitivity [78],
which also renders difficult the comparison of similar
studies. Most persons with HPV infections or persons
who develop HPV-associated cancers do not develop
antibodies; in fact, only 40% of HPV-16 infections are
associated with the development of HPV-16 antibodies
[79,80]. The techniques for viral infection are based
on the detection of HPV DNA from samples, via either
signal amplification methods, such as hybrid capture, or
target amplification, such as polymerase chain reaction-
based assays. A paper-based HPV DNA screening test
[81] is also in the development as an HPV test. Coupled
with a single-step DNA extraction procedure, the paper-
based test being studied in India allows for dry collec-
tion of cervical cells, along with transportation and
storage at room temperature [81].
Hybrid Capture II (Digene Corporation, Gaithers-
burg, MD, USA) assay is the only commercially available
second-generation assay that has been approved by
the US Food and Drug Administration (FDA) at present
for the primary screening of women aged 30 years or
older and for management of atypical squamous cells
of undetermined significance (ASCUS) [82]. Although
both low- and high-risk HPV panels are available for
Hybrid Capture II, only the high-risk panel is commonly
used to detect HPV types in samples. The lack of speci-
ficity in determining the presence of a high-risk versus 
a low-risk HPV infection is a limitation of the Hybrid
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Capture II, which has a lower analytical but not the
necessarily clinical sensitivity compared with PCR [83].
Cervical Cancer Screening and 
HPV DNA Test
There has been a dramatic reduction in the incidence
and mortality of cervical cancer among US women in
the past 50 years from the second most common can-
cer and cause of cancer death to 11th in incidence and
13th in mortality [84]. This remarkable improvement is
largely attributed to the introduction of the Pap smear
evaluation, recognized as the world’s most successful
cervical cytology screening test for more than 40 years
[85]. The Pap smear is well integrated into the health
care system in many countries around the world to
improve survival and reduce mortality rates in cervical
cancer. Over 50 million Pap tests are performed each
year in the US [86]. Even so, despite current practices of
regular, high-quality gynecologic care and screening in
the US, the low sensitivity of cervical cytology has ren-
dered the screening program only about 75% effective
since its introduction in 1950 [87]. The International
Agency for Research on Cancer estimated the lifetime
risk for developing cervical cancer among women who
received regular annual cervical cytology screening to be
217 per 100,000 women (assuming a Pap test sensitivity
of 70%) [88]. In the UK, Sasieni et al reported that 47%
of women diagnosed with stage 1B1 invasive cervical
cancer or worse before the age of 70 years had an ade-
quate previous screening history, and some had had
normal annual Pap smears [89]. Although the Pap test
possesses a relatively high specificity (80–85%), it suffers
from low sensitivity (50–60%) for high-grade CIN
(grades 2 and 3) and is even less sensitive for lower grade
lesions (CIN 1) [90]. Many rounds of screening are often
required for the detection of cervical cancer and precan-
cerous lesions [91]. The cost of multiple screenings,
follow-up and treatment has turned HPV infection
into one of the most costly STIs in the US [92]. The lat-
est revised guidelines by various professional organi-
zations, such as the American Cancer Society (ACS)
and the American College of Obstetrics and Gynecology
(ACOG), now recommend that cervical cancer screen-
ing should begin at 21 years of age or within 3 years of
the first sexual activity [93–99]. Additionally, some
organizations (ACS and ACOG) also advocate hrHPV
DNA testing as well as liquid-based cytology tests as an
adjunct to the Pap smear for primary cervical screen-
ing [98,99]. The US Agency of Health Care Policy and
Research and the UK National Institute for Clinical
Excellence have both recommended the liquid-based
cytology as a cost-effective alternative to the conven-
tional smear-based cytology [60]. The FDA has approved
two liquid-based cytology methods: the Sure-Path sys-
tem and the ThinPrep Pap Test. Cells scraped from the
cervix are examined directly on a slide in the traditional
Pap test, whereas the cells are first suspended and then
applied to a glass slide in the liquid-based technique,
removing much of the mucus, blood, and inflammatory
cells. Although liquid-based methods are more expensive
than conventional Pap tests, they possess higher sensitiv-
ity, probably due to the sample preparation method
[100]. It is estimated that the ThinPrep (Cytyc Corpora-
tion, Marlborough, MA, USA) liquid-based cytology
has a sensitivity of 80% for the detection of CIN [60].
The development of new technologies to identify pre-
cancerous cervical lesions with greater sensitivity and
predictive value than the Pap test has been an ongoing
objective for many gynecologic oncologists around the
world. Research on the role of HPV DNA testing for
cervical screening and management following an abnor-
mal Pap test began in the late 1980s [101]. Molecular
tests for the clinical detection of HPV have been devel-
oped for use in primary cervical screening and for
women with abnormal cervical cytology [102–108]. The
dependency of cervical cancer on HPV infection has
highlighted the clinical benefits of HPV DNA testing as
particularly significant. Several studies have reported a
high sensitivity of 100% (95% confidence interval [CI],
89–100) and a negative predictive value of 100% (95%
CI, 91–100) for this adjunctive approach using the
Hybrid Capture II [106]. A single liquid-based Pap test
is consistently reported to be 10% to 25% less sensitive
than a single HPV test for the detection of CIN 3 or
cancer, whereas the difference between the conven-
tional Pap smear and HPV testing is consistently much
greater (25–40%) [33,103–112]. However, the specificity
of the combined tests was slightly lower than that of the
Pap smear test alone. There is minimal risk of invasive
cervical cancer for at least the subsequent 3 to 5 years
when women have both a negative Pap and a negative
HPV DNA test [99]. Sherman et al [113] demonstrated
that the risk of a CIN 3 during the first 45 months of
follow-up after a single negative hrHPV test at the time
of enrollment was only 0.24% and was 0.87% after 
10 years in the 10-year National Cancer Institute-
Portland, Oregon cohort study consisting of 23,000
women who had had routine cytology screening. In
contrast, the risk for CIN 2/3 remained high (4.4%) for
initially HPV-positive women at 45 months and re-
mained more than 7% at 10 years. These findings led
the ACS, ACOG, and “Interim Guidance” to recommend
that the subsequent combined Pap and HPV test
should be done at least once in 3 years [93,97,99].
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A normal Pap test result with a negative HPV test
provides better prognostic assurance against the risk
of future CIN 3 or high-grade disease than three subse-
quent negative conventional Pap tests for women aged
30 years and older and allows the safe extension of the
interval from 3 to 5 years between cervical screenings
[90,99]. Women younger than age 30 years have a high
rate of hrHPV infection (15–46%), and most women
testing positive have only transient infections [35,36,
114]. This may potentially result in the overtreatment
of many women who have only transient HPV infec-
tions, thereby incurring unnecessary cost as well [115].
Only persistent hrHPV infection indicates that a patient
is at risk for developing CIN 2/3 and cancer, and HPV
positivity in sexually active women aged 30 years or
younger is less likely to imply persistent HPV infection
and high-grade lesions (CIN 2/3), unless the Pap results
indicate ASCUS. HPV DNA testing is also recommended
as an alternative to additional procedures (colposcopy
and cytology) that often accompany an abnormal Pap
result for follow-up of treated cases. Repeat HPV test-
ing for persistent HPV infection should be performed
after a year, because the usual clearance time reported
for transient infection is 6–12 months [96,99]. Any
woman remaining HPV positive should be referred 
for colposcopy, because there is a 1-in-4 risk for HPV-
positive ASCUS to have CIN 2/3 during the subse-
quent 2-year follow-up [116], and approximately 1 in
500 women already has invasive cervical cancer [117].
Prophylactic HPV Vaccines
The discovery that HPV is etiologically linked with cer-
vical cancer and genital warts has encouraged the
development of vaccines that can potentially prevent
cervical cancer. Prophylactic vaccination is given
before HPV infection in order to help the immune sys-
tem recognize and prevent viral entry before infection
or before the disease becomes fully established in 
the host body. The vaccine needs to generate virus-
neutralizing antibodies directed against the L1 and L2
capsid proteins that play a role in viral entry. The pro-
phylactic vaccine approach became possible in 1991,
after Zhou et al demonstrated that the HPV-16 L1
capsid proteins self-assembled into conformational
VLPs that resembled native virions in a recombinant
system [118]. VLP particles do not contain viral DNA
and pose no infectious or oncologic risk to the individ-
ual receiving the vaccine. These particles are empty
capsids that contain the major neutralizing epitopes
(part of a macromolecule recognized by antibodies, 
B cells or T cells) of the native virion necessary for the
induction of neutralizing antibodies [119,120]. The
only problem that arises with this approach is that L1
VLP vaccines give type-specific protection [118,121].
Since HPV-16 and -18 account for approximately 70%
of cervical cancers, vaccine development has focused
on these hrHPV types. These vaccines can potentially
prevent cervical cancers, cervical (CIN 1–3 and ade-
nocarcinoma in situ), vaginal (VAIN 2/3) and vulvar
(VIN 2/3) precancerous lesions.
The Merck vaccine (Gardasil) is a quadrivalent vac-
cine with HPV-6, -11, -16 and -18 VLPs and an adjuvant
aluminum hydroxide that boosts immune response.
Recombinant DNA technology has been used to pro-
duce L1 VLPs in recombinant yeast Saccharomyces cere-
visiae. The results of the double-blind, randomized
phase II trial of 2,392 women using the Merck vaccine
demonstrated that the administration of HPV-16 L1
VLP vaccine reduced the incidence of both HPV-16
infection and HPV-16-related CIN [122]. The primary
endpoint of this trial in the 2,392 young women was
persistent HPV-16 infection (detection in consecutive
visits) and HPV-16-related CIN. In 16- to 23-year-old
women who were HPV-16-naïve at baseline, the vaccine
was 100% effective; HPV-16 and CIN were detected in
41 unvaccinated (placebo) women but not in vaccinated
women. The vaccine was generally well-tolerated, and
there were no serious vaccine-related adverse events.
Moreover, in a recent clinical trial, the Merck vaccine
has demonstrated an overall 90% reduction in incident
or persistent infection or genital disease associated
with HPV types 6, 11, 16, and 18 [123]. Gardasil has
completed phase III clinical trials and was licensed by
the FDA on 8 June 2006 for use among girls and young
adult females aged 9 to 26 years [124]. Gardasil is
administered in a three-dose regimen as three 0.5-mL
intramuscular injections (at 0, 2, and 6 months), which
allows for the simultaneous injection of hepatitis B
vaccine at a separate injection site, as stated in the
package insert. The vaccine needs to be administered
before people become sexually active, so it has been
recommended for girls as young as 11 and 12 years of
age over a 6-month period by the Advisory Committee
on Immunization Practices, with catch-up immuniza-
tion for girls and women 13 to 26 years of age and 
vaccination of girls at ages 9 and 10 at the provider’s
discretion [124]. A Stanford University study revealed
that an effective vaccine could prevent 1,300 deaths if
all 12-year-old girls currently living in the US received
the vaccination, and that the cost of administering
such a vaccine would be far less than the medical costs
incurred by HPV [125]. Additional clinical trials are
currently underway to establish the efficacy of the Merck
quadrivalent vaccine. Other ongoing studies include
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evaluating the effectiveness of Gardasil in boys and
men aged 16 to 26 years, as well as in adult women
aged 24 to 45 years [126]. It is important to evaluate
the effect of vaccination in men, because HPV is linked
to genital warts, as well as oropharyngeal, esophageal,
penile and anal cancers in men; and vaccinating the
men may also prevent transmission to women [127].
The other candidate vaccine (Cervarix) is a bivalent
vaccine with HPV-16 and -18 VLPs, with an aluminum
salt plus monophosphoryl lipid A (AS04) adjuvant to
boost the immune response, currently under develop-
ment by GlaxoSmithKline (GSK). The GSK vaccine is
produced using baculovirus-infected insect cells. Similar
to Gardasil, it is administered as three 0.5-mL intra-
muscular injections. However, the timing is different; it
is to be given at 0, 1, and 6 months. Cervarix also
appears to be up to 100% effective in preventing infec-
tions with HPV-16 and -18, as well as Pap test abnor-
malities and cervical dysplasia associated with these
types [128]. A recent report by Harper et al [128] also
suggested that Cervarix may provide cross-protection
against HPV types 31 and 45. Cervarix has also com-
pleted phase III clinical trials but is currently still under
review by the FDA; however, it was approved by the
Australian Therapeutic Goods Administration in May
2007 for girls and women aged 10 to 45 years.
The most recent data by Harper et al [128] and
Mao et al [129] suggest the extension of immunity
beyond 4 years for both Gardasil and Cervarix. Goldie
et al [130] reported that vaccination is expected to
reduce the lifetime risk of cervical cancer by 70% to 83%,
assuming that the HPV vaccine has an efficacy rate of
75% in the general population and that people maintain
current Pap screening patterns. Clinical trials are still
ongoing for both vaccines to determine the need for
booster immunizations. Although HPV VLPs induce high
titers of neutralizing antibodies even without adjuvant
[131], both companies probably included aluminum-
based adjuvants to reduce the dose required to induce
peak antibody titers and to stabilize the vaccine during
cold storage [132]. Alternate adjuvants might also be
used to extend the duration of protection or reduce
the number of immunizations.
Conclusion
The availability of both Merck and GSK HPV pro-
phylactic vaccines should have an immense impact 
on HPV infection rates. Merck’s quadrivalent vaccine
for HPV not only reduces the potential mortality from
HPV-induced cervical carcinoma, but it also protects
the women from genital warts. However, both vaccines
protect women against only two hrHPV types; they will
still need screening for cervical cancer and the other
hrHPV types that are responsible for the remaining 30%
of HPV-induced lesions. Nevertheless, many issues re-
main to be addressed, including the duration of immu-
nity, long-term safety, the optimal age for vaccination,
and the optimal program of screening for cervical le-
sions. Cervical disease will continue to be a public
health burden in developing nations. Both vaccination
and screening will be difficult to accomplish in less
developed countries. Women there frequently present
with advanced disease at diagnosis, and treatment facil-
ities are often limited in these developing countries.
This review of the literature should provide some back-
ground for the readers on recently available HPV DNA
testing and the administration of prophylactic vac-
cines. More importantly, it is our intention to summa-
rize current trends in the prevention of cervical cancer.
Although some clinical trials are still inconclusive, many
clinical improvements have been observed in recent
years. The expectation is that in a decade’s time, we
may observe a dramatic reduction of incidence of pre-
cursor lesions of this cancer, not only in Taiwan, but
also worldwide. It is believed that investigation of an
oral vaccine that could be easily delivered and admin-
istered in developing countries and a therapeutic vaccine
for active treatment of cervical cancer are two ongoing
objectives in the field of gynecologic oncology.
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